Carmat announces that it has reached the milestone of 50 implants of its total artificial heart, and provides an update on its achievements and prospects. 41 hospitals in 12 countries have been trained for implantations, including 33 for commercial activity.

The company posted sales of 2.8 ME in 2023, marked by a marked acceleration in sales in the fourth quarter, with 11 of the 17 implantations carried out during the year. It is targeting sales of 14 to 20 ME.

Carmat will launch a very short-term capital increase to extend the financial horizon beyond the end of January 2024 and partially finance the Company's 12-month needs, estimated at a minimum of 50 ME

Stéphane Piat, Chief Executive Officer of Carmat, comments: ''This milestone is an important success and also testifies to the recognition of our therapy by major names in cardiology''.

' Taken together, these advances provide a solid foundation for a large-scale commercial rollout, enabling Carmat to achieve its ultimate goal of bringing patients waiting for a human heart a therapeutic solution and comfort of life. We look forward to 2024 with confidence and great determination to achieve the goals we have set ourselves. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.